Flurbiprofen is a nonsteroidal anti-inflammatory drug (NSAID) used to relieve pain, reduce inflammation, and fever.
Flurbiprofen (Dosage)
Flurbiprofen is a nonsteroidal anti-inflammatory drug (NSAID) for the short-term relief of symptoms such as sore throat, dental, menstrual, muscle, and postoperative pain. It is used as a symptomatic treatment for osteoarthritis, rheumatoid arthritis, soft tissue injuries such as bursitis and tendinitis, and after eye surgery.
MECHANISM OF ACTION
Flurbiprofen works by inhibiting the activity of cyclooxygenase enzymes (COX-1 and COX-2), which are responsible for the production of prostaglandins, substances that cause inflammation, pain, and fever.
CONTRAINDICATIONS
- Allergy to NSAIDs, aspirin, or any of the components of the medicine.
- History of gastrointestinal ulcers or gastrointestinal bleeding.
- Flurbiprofen should not be used with high doses of acetylsalicylic acid (more than 75 mg of Aspirin per day) or another NSAID medicine (such as celecoxib, ibuprofen, sodium diclofenac).
- Severe kidney or liver problems.
- Heart problems or high cardiovascular risk.
- Last trimester of pregnancy.
SIDE EFFECTS
The most frequent side effects are headache, dizziness, irritation and sore throat, itching and pruritus on the skin, mouth ulcers, and gastrointestinal discomfort. Allergic reactions such as asthma, skin rashes, difficulty breathing, palpitations, etc. may exceptionally occur. In case of an allergic reaction, stop taking the medicine and consult your doctor immediately.
Since flurbiprofen may increase the risk of gastrointestinal bleeding and cardiovascular events, it is recommended to use the lowest effective dose for the shortest possible time and under medical supervision, especially in patients at higher risk.
TRADE NAMES
- Ansaid®
- Strefen®
- Froben®
- Ocufen®
Genes analyzed
Bibliography
Dean L. Flurbiprofen Therapy and CYP2C9 Genotype. 2019 Feb 11. In: Pratt VM, Scott SA, Pirmohamed M, et al., editors. Medical Genetics Summaries [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2012-.
Loisios-Konstantinidis I, Cristofoletti R, Jamei M, et al. Physiologically Based Pharmacokinetic/Pharmacodynamic Modeling to Predict the Impact of CYP2C9 Genetic Polymorphisms, Co-Medication and Formulation on the Pharmacokinetics and Pharmacodynamics of Flurbiprofen. Pharmaceutics. 2020 Nov 2;12(11):1049.
Theken KN, Lee CR, Gong L, et al. Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2C9 and Nonsteroidal Anti-Inflammatory Drugs. Clin Pharmacol Ther. 2020 Aug;108(2):191-200.
